Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4454587
Max Phase: Preclinical
Molecular Formula: C24H25ClFN5O4
Molecular Weight: 501.95
Molecule Type: Unknown
Associated Items:
ID: ALA4454587
Max Phase: Preclinical
Molecular Formula: C24H25ClFN5O4
Molecular Weight: 501.95
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NCCCNC(=O)c1cc2cc(N3CC[C@](O)(C(=O)NCc4cc(F)cc(Cl)c4)C3=O)ccc2[nH]1
Standard InChI: InChI=1S/C24H25ClFN5O4/c25-16-8-14(9-17(26)12-16)13-29-22(33)24(35)4-7-31(23(24)34)18-2-3-19-15(10-18)11-20(30-19)21(32)28-6-1-5-27/h2-3,8-12,30,35H,1,4-7,13,27H2,(H,28,32)(H,29,33)/t24-/m0/s1
Standard InChI Key: NEFMYAUTOXJRLT-DEOSSOPVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 501.95 | Molecular Weight (Monoisotopic): 501.1579 | AlogP: 1.82 | #Rotatable Bonds: 8 |
Polar Surface Area: 140.55 | Molecular Species: BASE | HBA: 5 | HBD: 5 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 10.80 | CX Basic pKa: 9.72 | CX LogP: 0.19 | CX LogD: -1.82 |
Aromatic Rings: 3 | Heavy Atoms: 35 | QED Weighted: 0.24 | Np Likeness Score: -1.08 |
1. Heinrich T, Seenisamy J, Becker F, Blume B, Bomke J, Dietz M, Eckert U, Friese-Hamim M, Gunera J, Hansen K, Leuthner B, Musil D, Pfalzgraf J, Rohdich F, Siegl C, Spuck D, Wegener A, Zenke FT.. (2019) Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer., 62 (24): [PMID:31725285] [10.1021/acs.jmedchem.9b01070] |
Source(1):